Barry Simon Sells Shares of ImmunityBio, Inc.

Barry Simon, a key figure at ImmunityBio, Inc., sold 25,000 shares of the company on June 24, 2026. The shares were sold at an average price of $7.88 each, amounting to a total transaction value of $197,000. This sale was part of a planned transaction under Rule 10b5-1, a regulation that allows insiders to set up a predetermined plan to sell stocks.

Insider Buying and Selling at ImmunityBio, Inc.

On June 24, 2026, Barry Simon sold 25,000 shares of ImmunityBio at $7.88 per share, totaling $197,000 in a planned transaction. Earlier in June, several insiders, including Christobel Selecky and Bruce Wendel, each acquired 65,600 shares, indicating ongoing insider activity.

Other Institutional Activity in ImmunityBio, Inc.

Institutional investors have also been active in the stock. BlackRock, Inc. increased its holdings by 745,224 shares, bringing its total to 26,346,443 shares valued at approximately $202.08 million, marking a 2.9% increase. State Street Corp added 1,252,400 shares, ending with 17,708,103 shares worth about $135.82 million, a 7.6% increase. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, acquiring 16,322,844 and 15,127,714 shares respectively. D. E. Shaw & Co., Inc. also established a new stake with 12,571,597 shares.

ImmunityBio, Inc. Stock Up 8.1%

As of Saturday, ImmunityBio, Inc. (NasdaqGS: IBRX) shares traded near $7.79. The company has a market capitalization of approximately $8.16 billion and a forward P/E ratio of 129.8, indicating high expectations for future earnings. With a beta of 0.099, the stock shows low volatility compared to the broader market. Over the past year, its shares have ranged from a low of $1.95 to a high of $12.43. The stock's 50-day moving average is $7.56, while the 200-day moving average is $5.24.

Analysts Set New Price Targets

Analysts remain optimistic about ImmunityBio's potential. On May 21, 2026, BTIG reiterated its buy rating with a price target of $12. Piper Sandler also reiterated a buy rating on March 4, 2026, with a similar target. The consensus among analysts is a buy rating, with an average price target of $13 based on three opinions.

About ImmunityBio, Inc.

ImmunityBio, Inc. is a biotechnology company based in San Diego, California. It focuses on developing next-generation immunotherapies aimed at activating the immune system to fight cancer and infectious diseases. The company works on biologic products, including cytokine fusion proteins and cell therapies, and has collaborations with institutions like the National Cancer Institute. Under the leadership of CEO Richard Gerald Adcock, ImmunityBio employs 684 people.

Bottom Line

Barry Simon's planned sale of ImmunityBio shares is part of regular insider activity, which investors often watch for signals about company prospects. With a robust market cap and active institutional interest, ImmunityBio continues to be a focal point in the biotech sector. Analyst ratings suggest a positive outlook, but as always, these insights are backward-looking and should be considered with other factors.